{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-25-000003","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.238163+00:00","generated_at":"2026-05-28T03:49:27.478413+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Context Therapeutics appoints Andy Pasternak as Chairman; Richard Berman resigns from Board","bullets":["Richard Berman resigned from Board effective Jan 12, 2025; not due to any disagreement with the Company.","Andy Pasternak appointed Chairman effective Jan 13, 2025; term through 2027 annual meeting.","Pasternak also appointed to Audit and Compensation Committees; Dr. Karen L. Smith named Compensation Committee Chair.","Pasternak granted options to purchase 20,685 shares, vesting by June 13, 2025 or 2025 annual meeting; receives $55K annual cash retainer.","Pasternak brings 25+ years pharma experience, including role in $28B Horizon-Amgen acquisition and Bain Healthcare leadership."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-25-000003","json":"https://secwatch.observer/filing/0001842952-25-000003.json","markdown":"https://secwatch.observer/filing/0001842952-25-000003.md","text":"https://secwatch.observer/filing/0001842952-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000003/0001842952-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000003/cntx-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:49:27.478413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"567f632015","claim":"Richard Berman resigned as Director at Context Therapeutics Inc..","evidence_excerpt":"On January 10, 2025, Richard Berman gave notice of his resignation from the Board of Directors (the “Board”) of Context Therapeutics Inc. (the \"Company\"), effective as of January 12, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000003/0001842952-25-000003-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"70e6146073","claim":"Andy Pasternak was appointed as Chairperson of the Board at Context Therapeutics Inc..","evidence_excerpt":"the Board appointed Andy Pasternak as a member and Chairperson of the Board, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000003/0001842952-25-000003-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}